Top

Published in:

01-03-2013 | Breast Cancer (CI Falkson, Section Editor)

Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer: Controversies and Current Indications for Use

Authors: Lisa C. Klepczyk, MD, Kimberly S. Keene, MD, Jennifer F. De Los Santos, MD

Published in: Current Treatment Options in Oncology | Issue 1/2013

Opinion statement

Radiation therapy options for early-stage breast cancer have evolved during the past 40 years. Several choices are currently available to certain patient subsets that allow radiation oncologists to individualize care. Multiple phase II and several phase III trials have been published that support the safety and efficacy of accelerated partial breast irradiation (APBI) as part of breast conservation in selected patients. In contrast, a recent large retrospective analysis of patients aged 67 or older who received brachytherapy for APBI has raised concerns about its effectiveness. As the radiation community awaits results from NSABP B-39/RTOG 0413, the largest randomized trial of whole breast radiation therapy (WBRT) versus APBI, to provide more conclusive data, many academic and private radiation oncology practices are utilizing APBI off-protocol to treat early-stage breast cancer patients. Because of this, the American Society for Radiation Oncology (ASTRO) published a consensus statement in 2009 to aid in proper patient selection (Table 1). Until more definitive data is garnered, we advocate strict adherence to these selection criteria to ensure optimal outcomes. Specifically, we caution against the use of APBI in lymph node-positive disease outside of a clinical trial. There is a paucity of comparative data to guide oncologists in selection of the best APBI delivery method. The current NSABP B-39/RTOG 0413 trial allows any of the three most common forms of delivery to be utilized (multicatheter interstitial brachytherapy, balloon intracavitary brachytherapy, and external beam 3D conformal therapy) and will be instrumental to compare outcome differences between these methods.

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.PubMedCrossRef

Blichert-Toft M, Rose C, Andersen JA, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Conservation Cooperative Group. J Natl Cancer Inst Monogr. 1992;11:19–25.PubMed

van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92(14):1143–50.PubMedCrossRef

Poggi MM, Danforth DN, Sciuto LC, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer. 2003;98(4):697–702.PubMedCrossRef

Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.PubMedCrossRef

Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32.PubMedCrossRef

Arriagada R, Le MG, Rochard F, et al. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol. 1996;14(5):1558–64.PubMed

8.••

Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74(4):987–1001. Consensus guidelines from experts in radiation oncology on appropriate use of APBI outside of a clinical trial.PubMedCrossRef

Smith BD, Bentzen SM, Correa CR, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;81(1):59–68.PubMedCrossRef

10.

Greenup RA, Camp MS, Taghian AG, et al. Cost comparison of radiation treatment options after lumpectomy for breast cancer. Ann Surg Oncol 2012;19(10):3275–81.

11.

Albain KS, Green SR, Lichter AS, et al. Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol. 1996;14(11):3009–17.PubMed

12.

Nano MT, Gill PG, Kollias J, et al. Psychological impact and cosmetic outcome of surgical breast cancer strategies. ANZ J Surg. 2005;75(11):940–7.PubMedCrossRef

13.

Simmons RM, Fish SK, Gayle L, et al. Local and distant recurrence rates in skin-sparing mastectomies compared with non-skin-sparing mastectomies. Ann Surg Oncol. 1999;6(7):676–81.PubMedCrossRef

14.

Pelad AW, Foster RD, Stover AC, et al. Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts. Ann Surg Oncol. 2012;19(11):3402–9.CrossRef

15.

Bellon JR, Harris EE, Arthur DW, et al. ACR Appropriateness Criteria© conservative surgery and radiation—stage I and II breast carcinoma: expert panel on radiation oncology: breast. Breast J. 2011;17(5):448–55.PubMedCrossRef

16.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practical Guidelines in Oncology: Breast Cancer Version 3.2012. 2012;Available at www.nccn.com.

17.

Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.PubMedCrossRef

18.

Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–34.PubMedCrossRef

19.

van de Vijver MJ, He YD, Van’T Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999–2009.PubMedCrossRef

20.

van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–6.CrossRef

21.

Knauer M, Mook S, Rutgers EJ, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat. 2010;120(3):655–61.PubMedCrossRef

22.

Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.PubMedCrossRef

23.

Romond E, Perez E, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.PubMedCrossRef

24.

Joensuu H, Kellokumpu-Lehtinen P, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809–20.PubMedCrossRef

25.

Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–83.PubMedCrossRef

26.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. The Lancet 1998;351(9114):1451–67.

27.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.CrossRef

28.

Dowsett M, Cuzick J, Ingel J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509–18.PubMedCrossRef

29.

Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.CrossRef

30.

Nattinger AB, Hoffmann RG, Kneusel RT, et al. Relation between appropriateness of primary therapy for early-stage breast carcinoma and increased use of breast-conserving surgery. Lancet. 2000;356(9236):1148–53.PubMedCrossRef

31.

Gilligan MA, Kneusel RT, Hoffmann RG, et al. Persistent differences in sociodemographic determinants of breast conserving treatment despite overall increased adoption. Med Care. 2002;40(3):181–9.PubMedCrossRef

32.

Offerson BV, Overgaard M, Kroman N, et al. Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review. Radiother Oncol. 2009;90(1):1–13.CrossRef

33.

Beitsch PD, Shaitelman SF, Vicini FA. Accelerated partial breast irradiation. J Surg Oncol. 2011;103(4):362–8.PubMedCrossRef

34.

Edmundson GK, Vinici FA, Chen PY, et al. Dosimetric characteristics of the MammoSite RTS, a new breast brachytherapy applicator. Int J Radiat Oncol Biol Phys. 2002;52(4):1132–9.PubMedCrossRef

35.

Wilder RB, Curcio LD, Khanijou RK, et al. A Contura catheter offers dosimetric advantages over a MammoSite catheter that increase the applicability of accelerated partial breast irradiation. Brachytherapy. 2009;8(4):373–8.PubMedCrossRef

36.

Hattangadi JA, Powell SN, MacDonald SM, et al. Accelerated partial breast irradiation with low-dose-rate interstitial implant brachytherapy after wide local excision: 12-year outcomes from a prospective trial. Int J Radiat Oncol Biol Phys. 2012;83(3):791–800.PubMed

37.

Khan AJ, Arthur D, Vicini F, et al. Six-year analysis of treatment-related toxicities in patients treated with accelerated partial breast irradiation on the American Society of Breast Surgeons MammoSite Breast Brachytherapy registry trial. Ann Surg Oncol. 2012;19(5):1477–83.PubMedCrossRef

38.

Patel RR, Becker SJ, Das RK, et al. A dosimetric comparison of accelerated partial breast irradiation techniques: multicatheter interstitial brachytherapy, three-dimensional conformal radiotherapy, and supine versus prone helical tomotherapy. Int J Radiat Oncol Biol Phys. 2007;68(3):935–42.PubMedCrossRef

39.

Weed DW, Edmundson GK, Vicini FA, et al. Accelerated partial breast irradiation: a dosimetric comparison of three different techniques. Brachytherapy. 2005;4(2):121–9.PubMedCrossRef

40.

Vicini FA, Chen P, Wallace M, et al. Interim cosmetic results and toxicity using 3D conformal external beam radiotherapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer treated with breast conserving therapy. Int J Radiat Oncol Biol Phys. 2007;69(4):1124–30.PubMedCrossRef

41.

Sher DJ, Wittenberg E, Suh WW, et al. Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a cost effectiveness analysis. Int J Radiat Oncol Biol Phys. 2009;74(2):440–6.PubMedCrossRef

42.••

Vaidya JS, Joseph DJ, Tobias JS, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010;376(9735):91–102. One of only four randomized, controlled trials published to date on APBI. PubMedCrossRef

43.

Veronesi U, Orecchia R, Luini A, et al. Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons. Breast Cancer Res Treat. 2010;124(1):141–51.PubMedCrossRef

44.

Orecchia R, Ciocca M, Lazzari R, et al. Intraoperative radiation therapy with electrons (ELIOT) in early-stage breast cancer. Breast. 2003;12(6):483–90.PubMedCrossRef

45.

Shah C, Arthur D, Riutta J, et al. Breast-cancer related lymphedema: a review of procedure-specific incidence rates, clinical assessment aids, treatment paradigms, and risk reduction. Breast J. 2012;18(4):357–61.PubMedCrossRef

46.

Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98(9):599–609.PubMedCrossRef

47.

Del Bianco P, Zavagno G, Burelli P, et al. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial. Eur J Surg Oncol. 2008;34(5):508–13.PubMedCrossRef

48.

Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25(24):3657–63.PubMedCrossRef

49.

Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2):111–8.PubMedCrossRef

50.

Land SR, Kopec JA, Julien TB, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. J Clin Oncol. 2010;28(25):3929–36.PubMedCrossRef

51.

Coen JJ, Taghian AG, Kachnic LA, et al. Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2003;55(5):1209–15.PubMedCrossRef

52.

Shah C, Wilkinson JB, Baschnagel A, et al. Factors associated with the development of breast cancer-related lymphedema after whole-breast irradiation. Int J Radiat Oncol Biol Phys. 2012;83(4):1095–100.PubMedCrossRef

53.

Paskett ED, Dean JA, Oliveri JM, et al. Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review. J Clin Oncol 2012;30(30):3726–33.

54.

Shah C, Vicini FA. Breast-cancer related arm lymphedema: incidence rates, diagnostic techniques, optimal management and risk reduction strategies. Int J Radiat Oncol Biol Phys. 2011;81(4):907–14.PubMedCrossRef

55.

Davies NJ, Batehup L, Thomas R. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. Br J Cancer. 2011;105 Suppl 1:S52–73.PubMedCrossRef

56.

Ballard-Barbash R, Friedenreich CM, Courneya KS, et al. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104(11):815–40.PubMedCrossRef

57.

Chlebowski RT, Blackburn GL, Hoy MK, et al. Survival analysis from the Women’s Intervention Nutrition Study (WINS) evaluating dietary fat reduction and breast cancer outcome [abstract]. J Clin Oncol 2008;26(15S,Part I) Abstr 522.

58.

Livi L, Buonamici FB, Simontacchi G, et al. Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized clinical trial. Int J Radiat Oncol Biol Phys. 2010;77(2):509–15.PubMedCrossRef

59.•

Jagsi R, Ben-David MA, Moran JM, et al. Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76(1):71–8. Article raises concern with regards to the use of IMRT for APBI. PubMedCrossRef

60.

Pignol JP, Rakovitch E, Keller BM, et al. Tolerance and acceptance results of a Palladium-103 permanent breast seed implant phase I/II study. Int J Radiat Oncol Biol Phys. 2009;73:1482–8.PubMedCrossRef

61.

Kozak KR, Katz A, Adams J, et al. Dosimetric comparison of proton and photon three-dimensional, conformal, external beam accelerated partial breast irradiation techniques. Int J Radiat Oncol Biol Phys. 2006;65(5):1572–8.PubMedCrossRef

62.

Bush DA, Slater JD, Garberoglio C, et al. A technique of partial breast irradiation utilizing proton beam radiotherapy: comparison with conformal x-ray therapy. Cancer J. 2007;13(2):114–8.PubMedCrossRef

63.

Wang X, Amos RA, Zhang X, et al. External-beam accelerated partial breast irradiation using multiple proton beam configurations. Int J Radiat Oncol Biol Phys. 2011;80(5):1464–72.PubMedCrossRef

64.

Kozak KR, Smith BL, Adams J, et al. Accelerated partial breast irradiation using proton beams: initial clinical experience. Int J Radiat Oncol Biol Phys. 2006;66(3):691–8.PubMedCrossRef

65.

Fowble B, Solin LJ, Schultz DJ, et al. Breast recurrence following conservative surgery and radiation: patterns of failure, prognosis, and pathologic findings from mastectomy specimens with implications for treatment. Int J Radiat Oncol Biol Phys. 1990;19(4):833–42.PubMedCrossRef

66.

Fisher ER, Anderson S, Redmond C, et al. Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NSABP protocol B-06. Semin Surg Oncol. 1992;8(3):161–6.PubMed

67.

Gage I, Recht A, Gelman R, et al. Long-term outcome following breast-conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 1995;33(2):245–51.PubMedCrossRef

68.

Liljegren BG, Bergh HJ, Lindgren A, et al. 10-year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol. 1999;17(8):2326–33.PubMed

69.

Veronesi U, Marubini E, Mariani L, et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol. 2001;12(7):997–1003.PubMedCrossRef

70.

Malmstrom P, Holmberg L, Anderson H, et al. Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening. Eur J Cancer. 2003;39(12):1690–7.PubMedCrossRef

71.

Huang E, Buchholz TA, Meric F, et al. Classifying local disease recurrences after breast conservation therapy based on location and histology. Cancer. 2002;95(10):2059–67.PubMedCrossRef

72.

Bartelink H, Horiot J, Poortmans PM, et al. Impact of higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial. J Clin Oncol. 2007;25(22):3259–65.PubMedCrossRef

73.•

Antonucci JV, Wallace M, Goldstein NS, et al. Difference in patterns of failure in patients treated with accelerated partial breast irradiation versus whole-breast irradiation: a matched-pair analysis with 10-year follow up. Int J Radiat Oncol Biol Phys. 2009;74(2):447–52. Publication reports equal rates of ipsilateral breast tumor recurrence in patients receiving APBI compared with those receiving WBRT. PubMedCrossRef

74.

Beitsch PD, Wilkinson JB, Vicini FA, et al. Tumor bed control with balloon-based accelerated partial breast irradiation: incidence of true recurrences versus elsewhere failures in the American Society of Breast Surgery MammoSite® Registry Trial. Ann Surg Oncol 2012;19(10):3165–70.

75.

Arthur DW, Winter K, Kuske RR, et al. A phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of 95–17. Int J Radiat Oncol Biol Phys. 2008;72(2):467–73.PubMedCrossRef

76.•

Vicini F, Winter K, Wong J, et al. Initial efficacy results of RTOG 0319: three-dimensional conformal radiation therapy (3D-CRT) confined to the region of the lumpectomy cavity for stage I/II breast carcinoma. Int J Radiat Oncol Biol Phys. 2010;77(4):1120–7. Phase II trial shows early efficacy for the newest method of APBI delivery. PubMedCrossRef

77.•

Smith GL, Xu Y, Smith BD. Association between treatment with brachytherapy vs whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. JAMA. 2012;307(17):1827–37. Recent controversial study describes increased mastectomy rates in patients treated with APBI by multicatheter interstitial brachytherapy. PubMedCrossRef

78.

Cuttino LW, White JR, Rabinovitch R, et al. Accelerated partial-breast irradiation: trial by media or by science? Int J Radiat Oncol Biol Phys. 2012;83(4):1075–7.PubMedCrossRef

79.

Khan AJ, Vicini FA, Beitsch P, et al. Local control, toxicity, and cosmesis in women >70 years enrolled in the American Society of Breast Surgeons accelerated partial breast irradiation registry trial. Int J Radiat Oncol Biol Phys. 2012;84(2):323–30.PubMedCrossRef

80.

Kaufman SA, DiPetrillo TA, Price LL, et al. Long-term outcome and toxicity in a Phase I/II trial using high-dose-rate multicatheter interstitial brachytherapy for T1/T2 breast cancer. Brachytherapy. 2007;6(4):286–92.PubMedCrossRef

81.

Whelan T, et al. NCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer. J Clin Oncol. 2011;29(Abstr LBA1003 Suppl):S779.

82.

Chen PY, Vicini FA, Benitez P, et al. Long-term cosmetic results and toxicity after accelerated partial-breast irradiation: a method of radiation delivery by interstitial brachytherapy for the treatment of early-stage breast carcinoma. Cancer. 2006;106(5):991–9.PubMedCrossRef

83.

Vicini F, Beitsch PD, Quiet CA, et al. Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI). Cancer. 2008;112(4):758–66.PubMedCrossRef

84.

Chen PY, Wallace M, Mitchell C, et al. Four-year efficacy, cosmesis, and toxicity using three-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2010;76(4):991–7.PubMedCrossRef

85.•

Berrang TS, Olivotto I, Kim DH, et al. Three-year outcomes of a Canadian multicenter study of accelerated partial breast irradiation using conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2011;81(5):1220–7. Phase II, multi-center study shows excellent tumor control with minimal toxicity at 3 years. PubMedCrossRef

86.

Julian TB, Costantino JP, Vicini FA, et al. A randomized phase III study of conventional whole breast irradiation (WBI) vs partial breast irradiation (PBI) for women with stage 0, 1, or 2 breast cancer: NSABP B-39/RTOG 0413. 2011;San Antonio Breast Cancer Symposium:Abstract OT2-06-02.

87.

Ribeiro GG, Magee B, Swindell R, et al. The Christie Hospital breast conservation trial: an update at 8 years from inception. Clin Oncol (R Coll Radiol). 1993;5(5):278–83.CrossRef

88.

Dowdell DJ, Dyker K, Brown J. A randomised study of whole-breast vs. tumour-bed irradiation after local excision and axillary dissection for early breast cancer. Clin Oncol (R Coll Radiol). 2005;17(8):618–22.CrossRef

89.

Polgar C, Fodor J, Major T, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma: 5-year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69(3):694–702.PubMedCrossRef

Title: Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer: Controversies and Current Indications for Use
Authors: Lisa C. Klepczyk, MD
Kimberly S. Keene, MD
Jennifer F. De Los Santos, MD
Publication date: 01-03-2013
Publisher: Current Science Inc.
Published in: Current Treatment Options in Oncology / Issue 1/2013
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-012-0213-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 1/2013

How Do I Treat Inflammatory Breast Cancer?

Angiogenesis Inhibitors in the Treatment of Epithelial Ovarian Cancer

Considerations Regarding the Administration of Systemic Therapy for Elderly Patients With Ovarian Cancer

Novel Therapies for the Treatment of Advanced Prostate Cancer

Considerations in the Surgical Management of Ovarian Cancer in the Elderly

How Do I Screen Patients for Breast Cancer?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer